1. Coagulation dysfunction events associated with echinocandins: a real-world study from FDA adverse event reporting system (FAERS) database
- Author
-
Qian Cheng, Ye Wu, Zeyu Yao, Mengling Ouyang, Shupeng Zou, Xuan Shi, Yazheng Zhao, and Minghui Sun
- Subjects
Caspofungin ,Micafungin ,Anidulafungin ,Coagulation dysfunction ,FAERS ,Pharmacovigilance ,Diseases of the blood and blood-forming organs ,RC633-647.5 - Abstract
Abstract Background Echinocandins belong to the fourth generation of antifungals, and there are no systematic studies on their risk in coagulation dysfunction; this study will predict the risk of coagulation dysfunction of echinocandins using the US Food and Drug Administration Adverse Event Reporting System (FAERS) database. Method Data from January 2004 to March 2024 were obtained from FAERS. We examined the clinical characteristics of the coagulation dysfunction events and conducted disproportionality analysis by using reporting odds ratios (ROR) to compare echinocandins with the full database. Results There were 313 reports of coagulation dysfunction related to echinocandins as the primary suspect (PS) drug. The median time to incident for coagulation dysfunction was 3 (interquartile range [IQR] 1–9) days. Compared to triazoles and polyenes, echinocandins have a stronger signal (ROR 3.18, 95%CI 2.81–3.51, p
- Published
- 2024
- Full Text
- View/download PDF